Uniphar announces U.S. expansion, integrating leading companies and appointing new senior leadership
November 11, 2025 |
– New integration aligns U.S. operations, unifying RRD BioPharma Development, Uniphar Clinical, Diligent Health Solutions and BESTMSLs under the Uniphar brand.
– Mike Ebhardt is appointed President of Uniphar Pharma Services U.S., alongside Cindy Thompson as Vice President of Operations and Transformation.
[Dublin, November 2025] Uniphar, a global partner to pharmaceutical, medtech and biotech companies, announces a milestone in its expansion in the United States (U.S.); the integration and rebranding of RRD Biopharma Development, Uniphar Clinical, Diligent Health Solutions and BESTMSLs under the Uniphar name. This strategic move brings together market-leading clinical development expertise, medical affairs services including medical information, field team recruiting and medical communication capabilities, enabling Uniphar to deliver a seamless suite of services to its U.S. clients and an enhanced global offering across the product lifecycle.
As part of this transformation, RRD Biopharma Development, BESTMSLs and Diligent Health Solutions will align under Uniphar to support the delivery of its unified platform across Development, Clinical, Access, Medical, Commercial, Distribution and Global Sourcing. With locations in New York, North Carolina, Washington D.C. and Mississippi, Uniphar’s united presence ensures clients benefit from connected expertise, operational excellence and innovative solutions as one brand throughout the U.S., while leveraging Uniphar’s global infrastructure to deliver integrated solutions for clients beyond the U.S. market.
“Uniting our U.S. businesses under the Uniphar brand marks a transformative moment in our global strategy, strengthening our ability to deliver world-class integrated solutions at every stage of the product lifecycle, and ultimately driving better patient outcomes,” said Brian O’Shaughnessy, Chief Commercial Officer at Uniphar. “From molecule to market, our unparalleled expertise and unwavering commitment ensure we can support our clients through every phase of development and commercialization, providing innovative and seamless services in the U.S. and worldwide.”
In addition to the new integration, Uniphar will be expanding its U.S. senior leadership team through three strategic new appointments. Bringing more than 30 years of experience in the industry, Mike Ebhardt, in his new role as President of Uniphar Pharma Services U.S., will oversee Uniphar’s Development, Medical and Commercial services in the region. Previously, during his 18-year tenure at Conduent, Mike led the pharmaceutical and life sciences division, where he successfully increased revenue by 67% within two years. His extensive background also includes holding senior leadership positions at Xerox Life Sciences, TMS Health and Telerx. At Uniphar, Mike will focus on advancing the growth and market positioning of Uniphar in the U.S., while supporting the integration of BESTMSLs and other U.S. entities.
Cindy Thompson joins as Vice President of Operations and Transformation for Uniphar in the U.S. With over 17 years of experience in operational leadership and transformation within the pharmaceutical and life sciences sector, Cindy most recently served as Senior Director of Business Product Development at Conduent. She previously held a range of senior roles, including Director of Client Excellence and Global Lead for Transformation as well as Director of Marketing at TMS Health. At Uniphar, Cindy will lead initiatives to streamline processes, implement scalable operational models and ensure consistency and excellence across all U.S. businesses.
These appointments follow the recent hiring of Dr. Eric Rowinsky as Chief Medical Officer of the former RRD Biopharma Development, now Uniphar | Development. Dr. Rowinsky is a leading expert in oncology drug development with decades of experience in both academic research and biopharmaceutical leadership.
“Mike, Cindy and Eric’s extensive leadership and strategic expertise are pivotal to driving operational alignment and unlocking growth,” commented Brian O’Shaughnessy.
“Their appointments, alongside our ongoing U.S. investment, highlight the market’s significance to Uniphar’s strategy and our commitment to delivering integrated, high-impact solutions for our global clients.”
Uniphar’s ongoing expansion in the U.S. is marked by the opening of a new 65,000 sq. ft. GMP- and GDP-compliant pharmaceutical-grade facility in Raleigh, North Carolina. Alongside this investment, Uniphar maintains a strong international footprint across key markets in Europe, APAC and MENA.
This content was provided by Uniphar
Company Details
Latest Content from Uniphar
Uniphar announces U.S. expansion, integrating leading companies and appointing new senior leadership
- New integration aligns U.S. operations, unifying RRD BioPharma Development, Uniphar Clinical, Diligent Health Solutions and BESTMSLs under the Uniphar brand. - Mike Ebhardt is appointed President of Uniphar Pharma...
Uniphar On Track to Achieve SBTi Target of Halving Scope 1 and 2 Emissions by 2030
[Dublin, 9th October 2025] Uniphar, a global leader in pharmaceutical and medtech solutions, is making progress towards its near-term Science Based Targets initiative (SBTi) goal of halving Scope 1 and...
Streamlining European expansion for cell and gene therapies
Tom Smith, Strategic Director, Cell and Gene Therapies, Uniphar, discusses the essential elements biotechs need for commercial success in Europe’s unique market when developing cell and gene therapies (CGTs). Europe...
Current CGT landscape and future outlook
What makes CGT unique Cell and gene therapy (CGT) is a unique treatment that uses cells and genetic material to treat and cure diseases. Personalized to the patient, CGT’s offer...
Building for Success: Aligning Preclinical and Phase 1 Strategy with Commercial Goals
This article concludes our three-part series on preparing cell and gene therapies (CGTs) for successful launch and long-term viability. The first article explored the unique scientific and logistical challenges of...
Navigating the complexities of launch preparation for Cell and Gene Therapy
Cell and gene therapies (CGT) provide transformative treatment that can treat conditions that were previously considered untreatable. As described in the previous article in this series, most CGTs target patients...
Santhera Secures Agreement with Uniphar for the Distribution of AGAMREE® (Vamorolone) in five GCC (Gulf Cooperation Council) Countries
Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Uniphar to manage the distribution of AGAMREE® (vamorolone) in the United Arab Emirates, the Kingdom of Saudi Arabia,...
Uniphar Rebrands On Demand Business to Uniphar Global Sourcing, Strengthening Global Pharmaceutical Offering
Dublin, Ireland 16th July 2025 – Leading global healthcare services provider, Uniphar, has launched Uniphar | Global Sourcing, a new identity for its On Demand business that strengthens its position...
Uniphar Secures 10th Cell and Gene Therapy Project
[Dublin, April 17th 2025] Uniphar, a global leader in pharmaceutical and medtech solutions has announced the launch of its 10th cell and gene therapy (CGT) project. The milestone reinforces Uniphar’s...
Uniphar Expands Global Footprint with Three New Facilities in the USA, Netherlands and Ireland
[Dublin, 05 February 2025] Global partner to pharmaceutical and medtech manufacturers, Uniphar, is expanding its international presence with the launch of three new, state-of-the-art facilities, strategically positioned across key global...
- 1
- 2